While CiMaas is able to produce the required high numbers of natural killer (NK) cells intended to realise in the collaboration, we decided not to continue. Kiadis has refocused its clinical strategy to a concept of universal donors while CiMaas keeps working on the process of individual donors for each cancer patient where NK cells will be transfused in combination with a bone marrow transplantation.  

CiMaas, together with the Maastricht University, will facilitate a clinical trial in Multiple Myeloma patients who will receive the combination of selected donor derived NK cells and a bone marrow transplantation. In addition, CiMaas is creating alternative technologies to produce the same high numbers of NK cells for further clinical application, now based on its’ own technology.